NCT07915102 CAR-T Therapy: Safety, Efficacy, and Immune-Escape Mechanisms
| NCT ID | NCT07915102 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ciceri Fabio |
| Condition | CAR-T Cell Therapy |
| Study Type | OBSERVATIONAL |
| Enrollment | 225 participants |
| Start Date | 2023-02-02 |
| Primary Completion | 2030-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 225 participants in total. It began in 2023-02-02 with a primary completion date of 2030-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is a biological, drug-related, non-interventional observational study with both retrospective and prospective components. No experimental diagnostic procedures, investigational medicinal products, or medical devices will be used, and samples will be collected as part of routine clinical practice.
Eligibility Criteria
Inclusion Criteria: To achieve the objectives of this study, biological samples will be obtained from patients aged 18 years or older who meet at least one of the following inclusion criteria: * Patients eligible for CAR-T-cell therapy who have signed at least an initial informed consent for evaluation for this treatment at our center. * Patients who have previously signed the informed consent for the Hematological Malignancies Biobank (Biobanca Neoplasie Ematologiche) and for whom stored biological samples are available. * Patients eligible for bispecific antibody therapy who have signed at least an initial informed consent for evaluation for this treatment at our center. Exclusion Criteria: * Participation in clinical trial protocols that explicitly prohibit participation in biological observational studies.
Frequently Asked Questions
Who can join the NCT07915102 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying CAR-T Cell Therapy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07915102 currently recruiting?
Yes, NCT07915102 is actively recruiting participants. Visit ClinicalTrials.gov or contact Ciceri Fabio to inquire about joining.
Where is the NCT07915102 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT07915102 clinical trial?
NCT07915102 is sponsored by Ciceri Fabio. The trial plans to enroll 225 participants.